Last reviewed · How we verify
add-on sulphonylurea
add-on sulphonylurea is a Sulfonylurea Small molecule drug developed by Italian Society of Diabetology. It is currently FDA-approved for Type 2 diabetes mellitus as add-on therapy.
Sulfonylureas stimulate insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels, thereby lowering blood glucose in type 2 diabetes.
Sulfonylureas stimulate insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels, thereby lowering blood glucose in type 2 diabetes. Used for Type 2 diabetes mellitus as add-on therapy.
At a glance
| Generic name | add-on sulphonylurea |
|---|---|
| Sponsor | Italian Society of Diabetology |
| Drug class | Sulfonylurea |
| Target | ATP-sensitive potassium channel (KATP channel) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Sulfonylureas bind to and close ATP-sensitive potassium channels on the surface of pancreatic beta cells. This closure depolarizes the cell membrane, triggering calcium influx and subsequent insulin exocytosis. When used as add-on therapy, they complement other antidiabetic agents to enhance overall glycemic control.
Approved indications
- Type 2 diabetes mellitus as add-on therapy
Common side effects
- Hypoglycemia
- Weight gain
- Gastrointestinal disturbances
Key clinical trials
- Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3
- A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (PHASE4)
- GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM (PHASE4)
- DPP4 Inhibitor Intervention on Post-stroke Cognitive Impairment in Ischemic Stroke Patients With Type 2 Diabetes (PHASE3)
- A Study of BGM0504 in Participants with Type 2 Diabetes (PHASE3)
- Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM (PHASE4)
- Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration (PHASE4)
- Effect of Empagliflozin on Body Composition and Ketones (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- add-on sulphonylurea CI brief — competitive landscape report
- add-on sulphonylurea updates RSS · CI watch RSS
- Italian Society of Diabetology portfolio CI
Frequently asked questions about add-on sulphonylurea
What is add-on sulphonylurea?
How does add-on sulphonylurea work?
What is add-on sulphonylurea used for?
Who makes add-on sulphonylurea?
What drug class is add-on sulphonylurea in?
What development phase is add-on sulphonylurea in?
What are the side effects of add-on sulphonylurea?
What does add-on sulphonylurea target?
Related
- Drug class: All Sulfonylurea drugs
- Target: All drugs targeting ATP-sensitive potassium channel (KATP channel)
- Manufacturer: Italian Society of Diabetology — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus as add-on therapy
- Compare: add-on sulphonylurea vs similar drugs
- Pricing: add-on sulphonylurea cost, discount & access